STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer

References

• Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2014; 40:300-6; PMID:23931927; http://dx.doi.org/10.1016/j.ctrv.2013.07.002
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385-94; PMID:23724913; http://dx.doi.org/10.1056/NEJMoa1214886
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al. PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371:2167-77; PMID:25470694; http://dx.doi.org/10.1056/NEJMoa1408440
   PubMed Web of Science ®Google Scholar
• Lovly CM, Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med 2012; 4:120ps2; PMID:22323827; http://dx.doi.org/10.1126/scitranslmed.3003728
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012; 4:120ra17; PMID:22277784; http://dx.doi.org/10.1126/scitranslmed.3003316
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18:1472-82; PMID:22235099; http://dx.doi.org/10.1158/1078-0432.CCR-11-2906
   PubMed Web of Science ®Google Scholar
• Costa DB, Kobayashi S. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. J Thorac Oncol 2012; 7:623-5; PMID:22334013; http://dx.doi.org/10.1097/JTO.0b013e318241daab
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 2012; 18:6219-26; PMID:22843788; http://dx.doi.org/10.1158/1078-0432.CCR-12-0392
   PubMed Web of Science ®Google Scholar
• Yamaguchi N, Lucena-Araujo AR, Nakayama S, de Figueiredo-Pontes LL, Gonzalez DA, Yasuda H, Kobayashi S, Costa DB. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer 2014; 83:37-43; PMID:24199682; http://dx.doi.org/10.1016/j.lungcan.2013.09.019
   PubMed Web of Science ®Google Scholar
• Bosch-Barrera J, Menendez JA. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. Cancer Treat Rev 2015; 41:540-6; PMID:25944486; http://dx.doi.org/10.1016/j.ctrv.2015.04.008
   PubMed Web of Science ®Google Scholar
• Hong S, Chen N, Fang W, Zhan J, Liu Q, Kang S, He X, Liu L, Zhou T, Huang J, et al. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology 2015; 5:e1094598; PMID:27141355; http://dx.doi.org/10.1080/2162402X.2015.1094598
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang H, Zhao Q, Xia Y, Hu X, Guo J. PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med Oncol 2015; 32:212; PMID:26141060; http://dx.doi.org/10.1007/s12032-015-0655-2
   PubMed Web of Science ®Google Scholar
• Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer 2015; 14:149; PMID:26245467; http://dx.doi.org/10.1186/s12943-015-0421-2
   PubMed Web of Science ®Google Scholar
• Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol 2015; 51:221-8; PMID:25500094; http://dx.doi.org/10.1016/j.oraloncology.2014.11.014
   PubMed Web of Science ®Google Scholar
• Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH, et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget 2016; 7:15901-14; PMID:26893364
   PubMed Web of Science ®Google Scholar
• Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, et al. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res 2016; 22:609-20; PMID:26420858; http://dx.doi.org/10.1158/1078-0432.CCR-15-0876
   PubMed Web of Science ®Google Scholar
• Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S, Li S. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci Rep 2016 Jul 1; 6:28910; http://dx.doi.org/10.1038/srep28910
   PubMed Web of Science ®Google Scholar
• Lee Y, Shin JH, Longmire M, Wang H, Kohrt HE, Chang HY, Sunwoo JB. CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1. Clin Cancer Res 2016; 22:3571-81; PMID:26864211; http://dx.doi.org/10.1158/1078-0432.CCR-15-2665
   PubMed Web of Science ®Google Scholar
• Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Segura-Carretero A, Joven J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle 2013; 12:3390-404; PMID:24047698; http://dx.doi.org/10.4161/cc.26417
   PubMed Web of Science ®Google Scholar
• Cufí S, Bonavia R, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Cuyàs E, Martin-Castillo B, Barrajón-Catalán E, Visa J, Segura-Carretero A, et al. Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Sci Rep 2013; 3:2459
   PubMed Web of Science ®Google Scholar
• Cufí S, Bonavia R, Vazquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, Barrajón-Catalán E, Visa J, Segura-Carretero A, et al. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food Chem Toxicol 2013; 60:360-8; http://dx.doi.org/10.1016/j.fct.2013.07.063
   PubMed Web of Science ®Google Scholar
• Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014; 26:207-21; PMID:25065853; http://dx.doi.org/10.1016/j.ccr.2014.05.019
   PubMed Web of Science ®Google Scholar
• Hamedani FS, Cinar M, Mo Z, Cervania MA, Amin HM, Alkan S. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma. Leuk Res 2014; 38:503-8; PMID:24486291; http://dx.doi.org/10.1016/j.leukres.2013.12.027
   PubMed Web of Science ®Google Scholar
• You L, Shou J, Deng D, Jiang L, Jing Z, Yao J, Li H, Xie J, Wang Z, Pan Q, et al. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines. Oncotarget 2015; 6:40268-82; PMID:26384345
   PubMed Web of Science ®Google Scholar
• Shimoji M, Shimizu S, Sato K, Suda K, Kobayashi Y, Tomizawa K, Takemoto T, Mitsudomi T. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer 2016; 98:69-75; PMID:27393509; http://dx.doi.org/10.1016/j.lungcan.2016.04.021
   PubMed Web of Science ®Google Scholar
• Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, et al. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer 2016; 99:17-22; PMID:27565908; http://dx.doi.org/10.1016/j.lungcan.2016.06.006
   PubMed Web of Science ®Google Scholar
• Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, et al. Molecular Mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov 2016; 6:1118–1133
   Web of Science ®Google Scholar
• Zhao C, Li H, Lin HJ, Yang S, Lin J, Liang G. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism. Trends Pharmacol Sci 2016; 37:47-61; PMID:26576830; http://dx.doi.org/10.1016/j.tips.2015.10.001
   PubMed Web of Science ®Google Scholar
• Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK, Lee JC. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol 2013; 7:1093-102; PMID:23993685; http://dx.doi.org/10.1016/j.molonc.2013.08.001
   PubMed Web of Science ®Google Scholar
• Bosch-Barrera J, Sais E, Cañete N, Marruecos J, Cuyàs E, Izquierdo A, Porta R, Haro M, Brunet J, Pedraza S, et al. Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget 2016; 7:32006-14; PMID:26959886
   PubMed Web of Science ®Google Scholar